

RESULTS PREVIEW

25 April 2025
Sweden
Capital Goods

Research analysts:

Mathias Carlson

Stockwik

Share price: SEK22.6

Fair value range: SEK32.0–37.0

A steady start in a challenging climate – Q1 preview

We forecast sales of SEK211m (201m), up 5% Y/Y, with EBITA of SEK8m (12m), equating to an EBITA margin of 4% (6%). Market conditions remain subdued, but we expect the company to continue building on the operational progress seen in 2024, which marked a clear turning point in profitability. Local optimisation, leaner cost structures, and more focused sales execution – particularly in the Industrial and Services segments – are helping to preserve margins, even as Health and Property Services face tougher headwinds.

Cash flow gains and lower net debt ease financial risk

Robust operating cash flow – up 47% in 2024 – was a standout achievement, forming the backbone of Stockwik's ongoing financial recovery. We expect this momentum to continue in 2025, underpinned by stronger EBITA and tighter working capital management. Net debt/EBITDA declined to 4.06x in Q4 (3.90x adj.), reflecting clear progress toward a more flexible balance sheet. While deleveraging is moving slower than initially projected, the pivot to organic growth and rising capital efficiency should support improved credit metrics and a more attractive financing outlook. This could also pave the way for resumed M&A activity further down the line.

Estimates unchanged, fair value range held at SEK32–37

We continue to see Stockwik as offering a compelling risk/reward balance. The combination of structural growth in decentralised niches, visible margin recovery, falling interest costs, and a conservative valuation underpins our view. The company's strategic shift in 2024 – from acquisition-driven expansion to organic growth and platform development – is delivering results. While macro uncertainty persists, we believe Stockwik is better equipped today than in the past to manage near-term volatility and generate long-term value.

Upcoming events

- Q1 Report: 16 May 2025
- Q2 Report: 22 Aug 2025
- Q3 Report: 07 Nov 2025
- Q4 Report: 13 Feb 2026

Changes in this report			
	From	To	Chg
EPS adj. 2025e	3.1	3.1	0%
EPS adj. 2026e	4.6	4.6	0%
EPS adj. 2027e	5.2	5.2	0%

Key facts	
No. shares (m)	6.3
Market cap. (USDm)	15
Market cap. (SEKm)	143
Net IB Debt. (SEKm)	381
Adjustments (SEKm)	0
EV (2025e) (SEKm)	523
Free float	82.0%
Avg. daily vol. ('000)	12
Risk	High Risk
Fiscal year end	December
Share price as of (CET)	25 Apr 2025 00:00

Key figures (SEK)	2024	2025e	2026e	2027e
Sales (m)	851	893	936	984
EBITA (m)	53	62	68	72
EBITA adj. (m)	53	62	68	72
EPS	-2.06	2.18	3.85	4.57
EPS adj.	-0.86	3.13	4.65	5.20
DPS	0.00	0.00	0.00	0.00
Sales growth Y/Y	4%	5%	5%	5%
EPS adj. growth Y/Y	+chg	+chg	48%	12%
EBITA adj. margin	6.2%	6.9%	7.3%	7.3%
EV/Sales	0.6	0.6	0.5	0.5
EV/EBITA adj.	9.3	8.5	7.4	6.8
EV/EBITA	9.3	8.5	7.4	6.8
EV/EBIT	10.9	9.4	8.0	7.2
P/E adj.	n.m.	7.2	4.9	4.3
P/BV	0.7	0.6	0.6	0.5
Dividend yield	0.0%	0.0%	0.0%	0.0%
FCF yield	8.5%	6.0%	12.0%	13.1%
ROCE	7.4%	8.7%	9.6%	10.0%
ROE adj.	-2.5%	9.1%	12.4%	12.4%
Net IB debt/EBITDA	4.0	3.7	3.3	3.1

Share price - 5Y



High/Low (12M) SEK30.9/14.7

Perf.	3M	6M	12M	YTD
Abs.	22.3	46.2	48.7	32.5
Rel.	32.2	53.7	50.9	36.5

Source: Carnegie Research, FactSet, Millstream & company data

This report has been commissioned and sponsored by Stockwik. Commissioned research is considered to be marketing communication (i.e. not investment research under MiFID II). This material may be subject to restrictions on distribution in certain areas. For more information, see disclosures and disclaimers at the end of this report

Equity story

Near term:
6–12m

Stockwik is well-positioned for near-term growth by implementing operational improvements and cost-saving measures, with a strategic focus on its strongest segments: Industry and Health. By prioritising efficiency gains and optimising operations, the company enhances profitability and builds resilience to navigate challenging market conditions. The Health segment continues to demonstrate stable growth, driven by consistent demand for healthcare services and ongoing efforts to streamline operations, including reducing reliance on external consultants. Simultaneously, the Industry segment benefits from its focus on proprietary products and efficient production processes, which enhance margins and strengthen its competitive advantage.

Long term:
5Y+

Stockwik's long-term growth strategy is anchored in scaling its operations within the Industry and Health segments through a balanced approach of organic growth and strategic acquisitions. The company is focused on creating a sustainable business model by leveraging its portfolio of low-cyclicality businesses to navigate market fluctuations effectively. In the Industry segment, Stockwik leverages its diversified business portfolio to maintain stable performance across economic cycles, while the Health segment addresses growing demand for healthcare services driven by societal trends such as population ageing and preventive care. By combining organic expansion with disciplined acquisitions, Stockwik ensures scalability and long-term profitability, aligning its business with evolving market demands and stakeholder expectations.

Key risks:

- An extended period of economic instability or high-interest rates could dampen demand in the Industry and Health segments, impacting the company's growth trajectory.
- Delays in implementing efficiency improvements or realising cost savings could limit profitability and hinder progress in the core segments.
- Changes in regulations or increased competition within healthcare services and industrial operations could increase costs and pressure margins.

Company description

Stockwik manages a portfolio of stable, profitable, and high-quality Swedish companies. Focused on smaller businesses, Stockwik acquires well-managed operations and supports their growth through organic development and complementary acquisitions. By combining the expertise of smaller companies with the stability of a larger organisation, Stockwik delivers sustainable value. With a diversified portfolio across various industries, the company minimises risk while ensuring consistent returns.

Key industry drivers

- Economic stability
- Diversification
- Healthcare trends
- Operational efficiencies

Cyclicality

Cyclicality: No

Not cyclical

Key peers

AddLife, Addtech, Bergman & Beving, Indutrade, Instalco, Lagercrantz, Lifco, Sdipitech, and Volati.

Industry outlook

- Growth opportunities in Industry and Healthcare
- Steady demand in low-cyclicality sectors
- Potential for acquisitive growth


Largest shareholders

Avanza Pension	9.2%
Nordnet Pensionsförsäkr	8.8%
Per Olof Nordberg	7.4%

Valuation and methodology

Our valuation employs a dual-method approach, integrating DCF analysis and relative valuation to ensure a comprehensive and balanced assessment. The DCF methodology leverages Stockwik's historically stable and profitable portfolio, enabling reliable projections of future cash flows. This approach incorporates key factors such as long-term growth estimates, sustainable operating margins, and a discount rate that reflects the risk and return profile of a small-cap Swedish company. Complementing this, our relative valuation uses industry-standard multiples such as EV/EBITA, benchmarked against a peer group of mature, acquisition-driven Swedish companies. This comparative analysis ensures that Stockwik's market positioning and operational efficiency are accurately reflected in its valuation.


Fair value range 12m




The upper end of our fair value range is derived from a DCF valuation, applying a WACC of 17% to future cash flows. This discount rate reflects a high inherent risk due to high financial leverage, small market capitalisation and limited net cash flow generation.

The lower end of our fair value range is derived from a relative valuation approach. We assign a target EV/EBITA multiple of 10x on EBITA(26e), slightly below the trendline and representing a 43% discount to the median multiple of 18x for the reference group.


Key metrics



PE 12m forward




Long term valuation trend



Source: Carnegie Research & company data


Key charts

Sales per industry segment, LTM %




Source: Carnegie Research, Company data

Sales vs. growth y/y (R12m)




Source: Carnegie Research, Company data

EBITA vs. EBITA margin (R12m)




Source: Carnegie Research, Company data

Earnings per share, SEK (R12m)




Source: Carnegie Research, Company data

Net debt vs. Net debt/EBITDA




Source: Carnegie Research, Company data


Sales vs. growth y/y




Source: Carnegie Research, Company data

EBITA vs. EBITA margin

Source: Carnegie Research, Company data

Earnings per share, SEK

Source: Carnegie Research, Company data

Net debt vs. Net debt/EBITDA

Source: Carnegie Research, Company data

Valuation and risks

We estimate a fair value of SEK32–37 per share. Our valuation range is derived using two complementary methods: 1) a DCF valuation, which reflects stable cash flows and a conservative required rate of return; and 2) a relative valuation, supported by comparisons with a carefully selected group of high-quality companies that justify our target multiple.

DCF assumptions

Stockwik's portfolio has historically delivered stable sales growth, averaging approximately 11% annually on a pro-forma basis, alongside consistent double-digit EBITDA margins. Based on this strong performance, we believe that a DCF valuation is a robust and suitable method for determining the fair value of the company's shares.

For the DCF calculation, we apply a discount rate, or WACC, of 17% to Stockwik's future cash flows. This discount rate reflects high inherent risk due to Stockwik's high financial leverage, small market capitalisation and limited net cash flow generation. As a reference point, Stockwik's bond interest rate is approximately 10.3% (STIBOR 3M + 8%). By definition, this implies that equity investors should demand a substantially higher return, which we estimate to be ~7%-points above the bondholders' required return.

In addition to its core operations, Stockwik holds a deferred tax asset valued at ~SEK80m, as recorded on its balance sheet. This value is derived from the company's total accumulated tax loss carry forwards, which amounted to ~SEK388m as of Q4(24). These carry forwards represent a deferred tax asset calculated as SEK388m multiplied by the corporate tax rate of 20.6%, resulting in a value of ~SEK80m.

The tax loss carry-forwards have no expiration date, which means Stockwik will be able to use this asset to enhance future cash flows by SEK80m. According to Swedish tax regulations, these carry-forwards can begin to be utilised starting in 2025. We have calculated the net present value of these future cash flow benefits and included SEK40m from this deferred tax asset in our DCF valuation.

Based on our DCF valuation we arrive at a fair value of SEK37 per share, which we use to derive the high end of our fair value range.

DCF assumptions - Summary	2025e	2026e	2027e	Average year			Terminal	
				4-5	6-10	11-15	16-20	period
Total sales growth	4.9%	4.8%	5.2%	5.2%	5.2%	5.2%	5.2%	2.0%
EBITDA margin	11.6%	11.8%	11.5%	11.5%	11.5%	11.5%	11.5%	11.5%
Depreciation % of sales	-4.7%	-4.5%	-4.2%	-4.2%	-4.2%	-4.2%	-4.2%	-4.2%
EBITA margin	6.9%	7.3%	7.3%	7.3%	7.3%	7.3%	7.3%	7.3%
Amortisations % of sales	-0.7%	-0.5%	-0.4%	-0.4%	-0.4%	-0.4%	-0.4%	0.0%
EBIT margin	6.2%	6.7%	6.9%	6.9%	6.9%	6.9%	6.9%	6.9%
Capex % of sales	-0.7%	-0.6%	-0.6%	-0.6%	-0.6%	-0.6%	-0.6%	-0.6%
Paid tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
NWC to sales	2.9%	3.6%	4.1%	4.1%	4.1%	4.1%	4.1%	4.1%
Sales	893	936	984	1,061	1,269	1,632	2,099	2,362
EBITDA	104	110	113	122	146	187	241	271
Capex	-6	-6	-6	-6	-8	-10	-13	-98
Taxes	-6	-6	-6	0	0	0	0	0
Other	-43	-43	-45	-43	-44	-44	-45	961
Free cash flow	48	55	56	72	94	133	183	1,134
Discounted FCF	45	44	38	39	30	20	13	58
Share of total discounted FCF	8%	8%	7%	14%	26%	17%	11%	10%
Valuation	SEKm Per share		WACC assumptions					
EV (discounted FCF)	575	91	Risk free interest rate					
- Net debt (2024)	-386	-61	Debt risk premium					
+ Associates	0	0	Equity risk premium					
- Minority interest	0	0	Equity beta					
- Outstanding warrants	0	0	Cost of Equity					
Other debt adjustments	40	6	Tax rate					
ESG penalty	0	0	After tax cost of debt					
Equity value at YE (24)	229	36	Equity weight					
Time adjustment	5	1	WACC					
Dividend	0	0						
Current equity value	233	37						

Source: Carnegie Research

Relative valuation assumptions

Stockwik's investment strategy focuses on acquiring high-quality, stable, and profitable small- to medium-sized companies, making it a growth-through-acquisition company. For this reason, it is relevant to compare Stockwik with a group of Swedish acquisition-driven companies to determine a fair value for its shares. This approach also serves as a useful complement to our DCF valuation.


We have identified nine Swedish acquisition-driven companies that we believe are representative for a relative valuation. These companies are characterised by their maturity, operational excellence, and extensive track records of successful acquisitions within their respective niches. Our reference group includes AddLife, Addtech, Bergman & Beving, Indutrade, Instalco, Lagercrantz, Lifco, Sdiptech, and Volati.

Although Stockwik is a younger and smaller company than the reference group, we find the comparison relevant and appropriate, given Stockwik's long-term strategy and vision. Notably, Stockwik drew significant inspiration from Addtech and Indutrade when designing its investment philosophy and acquisition strategy at its founding in 2013.

To support our relative valuation, we selected two analytical approaches that provide insight into how the market values acquisition-driven companies. The first approach evaluates EV/EBITDA relative to EBITA margins to determine the multiples the market is willing to pay for profitability.


The second examines net debt/EBITDA relative to EV/EBITDA to assess how leverage impacts valuation multiples. In our analysis, we use EV multiples and margins based on 2026 estimates, as illustrated in the charts below.

EV/EBITA vs. EBITA margin



Source: Carnegie Research, Factset

Net debt/EBITDA vs. EV/EBITDA



Source: Carnegie Research, Factset

Both analyses reveal clear trends and correlations, though some outliers exist, and additional data points would be required for statistical significance. Stockwik stands out in these analyses with multiples below the trendline and a pronounced deviation concerning leverage.

For our relative valuation, we assign Stockwik a target EV/EBITA multiple of 10x on EBITA(26e), slightly below the trendline and representing a 43% discount to the median multiple of 18x for the reference group. We discount this target multiple using our 17% required rate of return, resulting in a fair value of SEK32 per share, which we use to derive our low end of our fair value range.

Company	EV/EBITDA (x)			EBITDA-margin (%)			EV/EBITA (x)			EBITA-margin (%)			Net debt/EBITDA (x)			Net debt-to-equity ratio (x)		
	25e	26e	27e	25e	26e	27e	25e	26e	27e	25e	26e	27e	25e	26e	27e	25e	26e	27e
AddLife	14.8	13.8	12.9	15.2	15.2	15.5	19.4	17.6	16.4	11.6	11.9	12.1	2.4	1.8	1.2	0.7	0.5	0.3
Addtech	23.1	21.6	20.9	16.8	17.1	16.9	25.9	24.1	23.6	15.0	15.3	15.0	0.9	0.4	0.0	0.4	0.2	0.0
Bergman & Beving	12.3	11.7	10.5	14.8	15.3	16.1	17.4	16.2	15.1	10.4	11.1	11.2	2.3	1.8	1.1	0.7	0.6	0.4
Indutrade	18.0	16.8	16.0	17.8	18.0	18.1	21.8	20.5	19.4	14.7	14.8	14.9	1.0	0.5	0.1	0.3	0.2	0.0
Instalco	9.3	7.8	7.2	9.6	10.6	10.9	12.6	10.6	9.6	7.1	7.8	8.1	2.4	1.7	1.1	0.9	0.6	0.4
Lagercrantz	21.5	20.3	19.6	21.2	21.5	21.5	25.3	24.0	22.9	18.1	18.1	18.5	1.3	0.8	0.3	0.6	0.3	0.1
Lifco	24.0	22.3	21.3	25.7	26.0	25.2	27.2	25.7	24.0	22.7	22.6	22.4	1.2	0.8	0.3	0.4	0.2	0.1
Sdiptech	7.6	7.3	7.0	23.8	23.6	23.6	9.3	8.8	8.4	19.5	19.7	19.7	2.9	2.4	1.9	0.8	0.6	0.4
Volati	10.2	9.3	8.8	12.7	13.3	13.7	12.9	11.5	10.9	10.1	10.7	11.0	2.6	2.1	1.6	1.4	1.1	0.7
Mean	15.7	14.5	13.8	17.5	17.9	17.9	19.1	17.7	16.7	14.3	14.7	14.8	1.9	1.4	0.8	0.7	0.5	0.3
Median	14.8	13.8	12.9	16.8	17.1	16.9	19.4	17.6	16.4	14.7	14.8	14.9	2.3	1.7	1.1	0.7	0.5	0.3
Stockwik	5.1	4.6	4.3	11.6	11.8	11.5	8.5	7.4	6.8	6.9	7.3	7.3	3.7	3.3	3.1	1.7	1.5	1.2

Source: Carnegie Research, Factset

An analysis of the charts above highlights the strong correlation between leverage and valuation, supporting our view that reducing leverage is a key driver for unlocking value for Stockwik's shareholders in the near term.

Stockwik is a young acquisition-driven company that has successfully built a well-diversified portfolio of businesses, primarily financed through significant borrowing. This high level of debt increases Stockwik's financial risk, which negatively affects the valuation of its shares. However, its portfolio demonstrates stable and solid profitability, which positions it well to weather the current economic downturn and supports the potential for a revaluation of its shares.

Once Stockwik's leverage ratio falls to the range of 2.0–2.5x net debt/EBITDA and its financial costs return to more normal levels, we expect the company's growth trajectory to accelerate. In our view, Stockwik's cautious and value-driven investment strategy holds strong potential for generating sustainable long-term value growth.

Risks

The near-term upside hinges on the successful implementation of its cost-saving measures and operational improvements across its portfolio, particularly within the Health and Industry segments. By focusing on streamlining processes and optimising operations, we expect the company to enhance margins, strengthen cash flow, and improve financial stability. Additionally, steady demand in low-cyclicality sectors such as healthcare and industrial services could drive organic growth and support a favourable re-rating of valuation multiples.

The downside risks include macroeconomic uncertainties, such as prolonged economic slowdowns or elevated interest rates, which may suppress demand in key segments and delay efforts to reduce the company's high debt levels. Challenges in realising anticipated efficiency gains or cost savings could constrain profitability and hinder progress.

Interim figures

Carnegie estimates		2024				2025e							
SEKm	Q1	Q2	Q3	Q4	Q1e	Q2e	Q3e	Q4e	2024	2025e	2026e	2027e	
Sales	201	214	183	254	211	224	192	266	851	893	936	984	
growth (Y/Y)	4.1%	1.3%	5.4%	4.6%	5.1%	4.9%	5.1%	4.6%	4.0%	4.9%	4.8%	5.2%	
organic growth (Y/Y)	4.1%	1.3%	5.4%	4.6%	5.1%	4.9%	5.1%	4.6%	4.0%	4.9%	4.8%	5.2%	
Gross income	131	134	91	145	124	131	112	155	502	522	549	575	
margin	65%	63%	50%	57%	59%	59%	59%	59%	59%	58.5%	59%	58%	
EBITA	12	6	13	22	8	12	14	28	53	62	68	72	
margin	6.0%	2.9%	6.9%	8.6%	3.8%	5.4%	7.0%	10.5%	6.2%	6.9%	7.3%	7.3%	
EBIT	10	4	11	20	7	11	12	27	45	56	63	68	
margin	4.9%	1.9%	6.0%	7.9%	3.1%	4.7%	6.3%	10.0%	5.3%	6.2%	6.7%	6.9%	
Net financials	-14	-13	-12	-13	-10	-10	-10	-10	-52	-40	-36	-36	
PTP	-4	-9	-1	7	-4	0	2	16	-6	15	27	32	
Tax	1	0	1	-8	0	0	0	0	-7	-2	-3	-3	
Tax rate	14%	4%	56%	120%	-11%	85%	20%	2%	-110%	10%	10%	10%	
Net income	-3	-9	0	-1	-4	0	2	16	-13	14	24	29	
EPS									-2.1	2.2	3.9	4.6	
DPS									0.0	0.0	0.0	0.0	

Source: Carnegie Research, Company data

Financial statements

Profit & loss (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Sales	127	346	427	585	765	818	851	893	936	984
COGS	-64	-192	-229	-268	-346	-314	-349	-370	-387	-409
Gross profit	63	154	198	316	418	504	502	522	549	575
Other income & costs	-58	-123	-161	-248	-335	-415	-406	-419	-439	-462
Share in ass. operations and JV	0	0	0	0	0	0	0	0	0	0
EBITDA	5	31	37	69	83	90	96	104	110	113
Depreciation PPE	-1	-12	-17	-22	-28	-40	-43	-42	-42	-41
Depreciation lease assets	0	0	0	0	0	0	0	0	0	0
Amortisation development costs	0	0	0	0	0	0	0	0	0	0
Amortisation other intangibles	0	0	0	0	0	0	0	0	0	0
Impairments / writedowns	0	0	0	0	0	0	0	0	0	0
EBITA	4	19	20	47	55	50	53	62	68	72
Amortization acquisition related	-3	-7	-9	-16	-16	-12	-8	-6	-5	-4
Impairment acquisition related	0	0	0	0	0	0	0	0	0	0
EBIT	1	12	11	31	39	38	45	56	63	68
Share in ass. operations and JV	0	0	0	0	0	0	0	0	0	na
Net financial items	-3	-14	-25	-30	-39	-61	-52	-40	-36	-36
of which interest income/expenses	-3	-14	-25	-30	-39	-61	-52	-40	-36	-36
of which interest on lease liabilities	0	0	0	0	0	0	0	0	0	0
of which other items	0	0	0	0	0	0	0	0	0	0
Pre-tax profit	-3	-2	-14	1	1	-24	-6	15	27	32
Taxes	20	29	14	-10	3	-13	-7	-2	-3	-3
Post-tax minorities interest	0	0	0	0	0	0	0	0	0	0
Discontinued operations	0	0	0	0	0	0	0	0	0	0
Net profit	17	28	0	-9	4	-37	-13	14	24	29
Adjusted EBITDA	5	31	37	69	83	90	96	104	110	113
Adjusted EBITA	4	19	20	47	55	50	53	62	68	72
Adjusted EBIT	1	12	11	31	39	38	45	56	63	68
Adjusted net profit	21	34	9	7	20	-25	-5	20	29	33
Sales growth Y/Y	44.9%	172.9%	23.3%	36.9%	30.8%	7.0%	4.0%	4.9%	4.8%	5.2%
EBITDA growth Y/Y	+chg	472.2%	20.1%	85.2%	20.7%	8.0%	6.9%	8.2%	6.3%	2.7%
EBITA growth Y/Y	+chg	375.0%	6.3%	130.2%	19.1%	-10.1%	6.4%	16.0%	10.6%	5.9%
EBIT growth Y/Y	+chg	1933.3%	-6.6%	171.1%	26.9%	-4.3%	21.1%	22.2%	13.5%	7.9%
EBITDA margin	4.3%	8.9%	8.7%	11.8%	10.8%	10.9%	11.2%	11.6%	11.8%	11.5%
EBITA margin	3.2%	5.5%	4.7%	8.0%	7.2%	6.1%	6.2%	6.9%	7.3%	7.3%
EBIT margin	0.5%	3.5%	2.7%	5.3%	5.1%	4.6%	5.3%	6.2%	6.7%	6.9%
Tax rate	714.3%	na	na	na	na	na	na	na	na	na
Cash flow (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
EBITDA	5	31	37	69	83	90	96	104	110	113
Paid taxes	-2	-6	-2	-10	-12	-5	-6	-6	-6	-6
Change in NWC	-1	4	10	-14	-6	6	19	-4	-4	-4
Non cash adjustments	0	-5	-1	-10	-1	12	0	0	0	1
Discontinued operations	0	0	0	0	0	0	0	0	0	0
Total operating activities	2	24	44	36	65	102	110	94	100	104
Capex tangible assets	-1	-2	-2	-1	-3	-4	-10	-6	-6	-6
Capitalised development costs	0	0	0	0	0	0	0	0	0	0
Capex - other intangible assets	0	0	0	0	0	0	0	0	0	0
Acquisitions/divestments	-18	-76	-62	-94	-99	-9	-17	-3	0	0
Other non-cash adjustments	0	0	0	0	0	0	0	0	0	0
Total investing activities	-19	-77	-63	-94	-102	-13	-26	-9	-6	-6
Net financial items	-3	-14	-25	-30	-39	-61	-52	-40	-36	-36
Lease payments	0	-8	-12	-16	-22	-33	-36	-39	-41	-43
Dividend paid and received	0	0	0	0	0	0	0	0	0	0
Share issues & buybacks	0	0	13	138	3	0	1	0	0	0
Change in bank debt	22	91	111	67	60	-109	0	0	0	0
Other cash flow items	0	0	0	0	1	0	0	0	0	0
Total financing activities	19	69	87	158	3	-203	-87	-79	-77	-79
Operating cash flow	2	24	44	36	65	102	110	94	100	104
Free cash flow	-2	0	6	-11	1	4	12	9	17	19
Net cash flow	2	16	68	100	-34	-114	-3	5	17	19
Change in net IB debt	-20	-69	-32	48	-72	28	33	44	58	62
Capex / Sales	0.8%	0.6%	0.4%	0.2%	0.4%	0.5%	1.1%	0.7%	0.6%	0.6%
NWC / Sales	4.2%	4.8%	5.8%	6.3%	7.4%	7.3%	4.4%	2.5%	3.2%	3.8%

Source: Carnegie Research & company data

Financial statements, cont.

Balance sheet (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Acquired intangible assets	38	129	203	283	352	351	352	352	352	352
Other fixed intangible assets	8	28	69	87	104	91	83	77	72	68
Capitalised development	0	0	0	0	0	0	0	0	0	0
Tangible assets	4	9	10	21	24	15	20	17	11	6
Lease assets	0	19	24	37	53	68	78	87	98	111
Other IB assets (1)	0	0	0	0	0	0	0	0	0	0
Other non-IB assets	37	63	72	64	62	57	56	56	56	56
Fixed assets	86	248	378	492	594	582	589	589	589	593
Inventories (2)	0	17	22	33	57	48	48	51	53	56
Receivables (2)	16	56	70	94	104	105	104	109	115	120
Prepaid exp. & other NWC items (2)	7	6	9	16	20	25	0	0	0	0
IB current assets (1)	0	0	0	0	0	0	0	0	0	0
Other current assets	1	1	4	4	5	6	25	25	25	25
Cash & cash equivalents (1)	3	19	87	187	153	39	37	42	60	77
Current assets	27	100	192	334	339	222	214	227	252	278
Total assets	113	347	570	825	932	804	803	816	841	872
Shareholders' equity	48	93	119	254	261	224	211	225	249	278
Minorities	0	0	0	0	0	0	0	0	0	0
Other equity	0	0	0	0	0	0	0	0	0	0
Total equity	48	93	119	254	261	224	211	225	249	278
Deferred tax	0	0	0	0	0	0	0	0	0	0
LT IB debt (1)	26	160	313	385	12	341	344	344	344	344
Other IB provisions (1)	0	0	0	0	0	0	0	0	0	0
Lease liabilities	0	16	22	35	49	65	75	75	75	75
Other non-IB liabilities	4	1	2	0	0	0	0	0	0	0
LT liabilities	30	178	337	420	61	406	420	420	420	420
ST IB debt (1)	13	12	4	24	457	18	4	4	4	4
Payables (2)	8	30	50	53	67	64	76	80	84	88
Accrued exp. & other NWC items (2)	8	23	28	39	51	58	58	54	50	47
Other ST non-IB liabilities	6	12	33	35	36	36	35	35	35	35
Liabilities - assets held for sale	0	0	0	0	0	0	0	0	0	0
Current liabilities	35	76	115	151	611	174	173	172	173	174
Total equity and liabilities	113	347	570	825	932	804	803	816	841	872
Net IB debt (=1)	36	169	252	257	365	385	386	381	364	346
Net working capital (NWC) (=2)	7	27	23	51	63	57	18	26	33	41
Capital employed (CE)	50	223	392	638	721	642	629	643	667	696
Capital invested (CI)	56	211	329	478	595	582	551	560	567	578
Equity / Total assets	42%	27%	21%	31%	28%	28%	26%	28%	30%	32%
Net IB debt / EBITDA	6.6	5.5	6.8	3.7	4.4	4.3	4.0	3.7	3.3	3.1
Per share data (SEK)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Adj. no. of shares in issue YE (m)	3.58	4.30	5.00	6.16	6.31	6.31	6.31	6.31	6.31	6.31
Diluted no. of Shares YE (m)	3.58	4.30	5.00	6.16	6.31	6.31	6.31	6.31	6.31	6.31
EPS	3.85	6.51	0.09	-1.50	0.61	-5.88	-2.06	2.18	3.85	4.57
EPS adj.	4.61	8.13	2.01	1.22	3.24	-3.93	-0.86	3.13	4.65	5.20
CEPS	4.93	8.95	3.16	2.38	4.16	-2.79	0.19	3.61	4.81	4.88
DPS	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
BVPS	13.3	21.6	23.8	41.3	41.4	35.4	33.5	35.6	39.5	44.1
Performance measures	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
ROE	46.5%	39.2%	0.4%	-4.6%	1.5%	-15.3%	-6.0%	6.3%	10.3%	10.9%
Adj. ROCE pre-tax	10.3%	14.2%	6.8%	10.2%	9.7%	7.6%	8.6%	9.7%	10.4%	10.6%
Adj. ROIC after-tax	-57.4%	14.2%	7.5%	11.5%	10.3%	8.5%	9.4%	11.1%	12.1%	12.6%
Valuation	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
FCF yield	-1.5%	-0.1%	3.9%	-7.9%	0.8%	2.9%	8.5%	6.0%	12.0%	13.1%
Dividend yield YE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Dividend payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Dividend + buy backs yield YE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
EV/Sales YE	0.90	0.88	1.64	1.41	0.65	0.60	0.58	0.59	0.54	0.50
EV/EBITDA YE	21.2	9.9	18.8	12.0	6.0	5.5	5.2	5.1	4.6	4.3
EV/EBITA YE	28.7	16.1	34.6	17.7	8.9	9.9	9.3	8.5	7.4	6.8
EV/EBITA adj. YE	28.7	16.1	34.6	17.7	8.9	9.9	9.3	8.5	7.4	6.8
EV/EBIT YE	>50	25.1	>50	26.6	12.6	13.2	10.9	9.4	8.0	7.2
P/E YE	5.7	4.9	>50	nm	33.3	nm	nm	10.4	5.9	4.9
P/E adj. YE	4.8	3.9	44.5	>50	6.3	nm	nm	7.2	4.9	4.3
P/BV YE	1.66	1.47	3.76	2.23	0.50	0.48	0.51	0.63	0.57	0.51
Share price YE (SEK)	22.1	31.7	89.4	91.9	20.5	17.1	17.1	22.6		

Source: Carnegie Research & company data

Disclosures and disclaimers

Carnegie Investment Bank AB

Carnegie Investment Bank AB (publ.) is a leading investment bank with a Nordic focus. The Carnegie group of companies, together "Carnegie", generates added value for institutions, companies and private clients in the areas of trade in securities, investment banking and private banking. Carnegie has approximately 600 employees, located in offices in six countries

Valuation, methodology, and assumptions

Commissioned research reports include the analyst's assessment of a fair value range over the coming six to 12 months based on various fundamental valuation methods. A commonly used method is DCF valuation, where future cash flows are discounted to today. Analysts may also use different valuation multiples, e.g. P/E ratio and EV/EBIT multiples, relative to industry peers. For companies where it is appropriate, a fair value range can also be based on the analyst's assessment of a fair ratio relative to the net asset value of the company. Fair value ranges represent the assessment of the analyst(s) at the time of writing

Frequency of update

Carnegie's research analysis consists of case-based analyses, which implies that the frequency of the analytical report may vary over time. Unless otherwise expressly stated in the report, the analysis is updated when considered necessary by the research department, for example in the event of significant changes in market conditions or events related to the issuer/the financial instrument.

Analyst certification

The research analyst or analysts responsible for the content of this commissioned research report certify that, notwithstanding the existence of any potential conflicts of interests referred to herein, the views expressed in this commissioned research report accurately reflect the research analyst's personal views about the companies and securities covered. It is further certified that the research analyst has not been, nor is or will be, receiving direct or indirect compensation related to the specific ratings or views contained in this commissioned research report.

Potential conflicts of interest

Carnegie, or its subsidiaries, may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any company mentioned in this report. Any such publicly announced business activity, during the past 12 months, will be referred to in this commissioned research report. A set of rules handling conflicts of interest is implemented in the Carnegie Group. Investment Banking and other business departments in Carnegie are surrounded by information barriers to restrict the flows of sensitive information. Persons outside such barriers may gain access to sensitive information only after having observed applicable procedures. The remuneration of persons involved in preparing this commissioned research report is not tied to investment banking transactions performed by Carnegie or a legal person within the same group.

Confidential and non-public information regarding Carnegie and its clients, business activities and other circumstances that could affect the market value of a security ("sensitive information") is kept strictly confidential and may never be used in an undue manner.

Internal guidelines are implemented in order to ensure the integrity and independence of research analysts. In accordance with the guidelines the research department is separated from the Investment Banking department and there are no reporting lines between the research department and Investment Banking. The guidelines also include rules regarding, but not limited to, the following issues; contacts with covered companies, prohibition against offering favourable recommendations, personal involvement in covered companies, participation in investment banking activities, supervision and review of research reports, analyst reporting lines and analyst remuneration.

Other material conflicts of interest

This report was commissioned and sponsored by the issuer (issuer-paid research).

Distribution restrictions

This commissioned research report is intended only for distribution to professional investors. Such investors are expected to make their own investment decisions without undue reliance on this commissioned research report. This commissioned research report does not have regard to the specific investment objectives, financial situation or particular needs of any specific person who may receive it. Investors should seek financial advice regarding the appropriateness of investing in any securities discussed in this commissioned research report and should understand that statements regarding future prospects may not be realized. Past performance is not necessarily a guide to future performance. Carnegie and its subsidiaries accept no liability whatsoever for any direct or consequential loss, including, without limitation, any loss of profits arising from the use of this commissioned research report or its contents. This commissioned research report may not be reproduced, distributed or published by any recipient for any purpose. The document may not be distributed to persons that are citizens of or domiciled in any country in which such distribution is prohibited according to applicable laws or other regulations.

This commissioned research report is distributed in Sweden by Carnegie Investment Bank AB. Carnegie Investment Bank AB is a bank incorporated in Sweden with limited liability which is authorised and regulated by the Swedish Financial Supervisory Authority (Finansinspektionen). In Finland this commissioned research report is issued by Carnegie Investment Bank AB, Finland Branch. The Finland branch is authorised by the Swedish Financial Supervisory Authority and subject to limited regulation by the Finnish Financial Supervisory Authority (Finanssivalvonta). In Norway this commissioned research report is issued by Carnegie AS, a wholly-owned subsidiary of Carnegie Investment Bank AB. Carnegie AS is regulated by the Financial Supervisory Authority of Norway (Finanstilsynet). In Denmark this commissioned research report is issued by Carnegie Investment Bank AB, Denmark Branch. The Denmark branch is authorised by the Swedish Financial Supervisory Authority and subject to limited regulation by the Danish Financial Supervisory Authority (Finanstilsynet).

This commissioned research report is distributed in the US by Carnegie, Inc., a US-registered broker-dealer and a member of FINRA and SIPC. Carnegie's research analysts located outside of the US are employed by non-US affiliates of Carnegie Inc. ("non-US affiliates") that are not subject to FINRA regulations. Generally, Carnegie research analysts are not registered with or qualified as research analysts with FINRA, and therefore are not subject to FINRA rule 2241 restrictions intended to prevent conflicts of interest by, among other things, prohibiting certain compensation practices, restricting trading by analysts and restricting communications with the companies that are the subject of the research report. Research reports distributed in the U.S. are intended solely for major US institutional investors and US institutional investors as defined under Rule 15a-6 of the Securities Exchange Act of 1934. This commissioned research report is provided for informational purposes only and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of any offer to buy any securities. Reports regarding equity products are prepared by non-US affiliates of and distributed in the United States by Carnegie Inc. under Rule 15a-6(a)(3). When distributed by Carnegie Inc, Carnegie Inc. takes responsibility for the commissioned research report. Any US person who wishes to effect transactions based on this commissioned research report should contact Carnegie Inc. Investors in the US should be aware that investing in non-US securities entails certain risks. The securities of non-US issuers may not be registered with, or be subject to, the current information reporting and audit standards of the US Securities and Exchange Commission.

This commissioned research report has been issued in the UK by Carnegie UK which is the UK Branch of Carnegie Investment Bank AB. Carnegie UK is authorised and regulated by the Financial Conduct Authority (FCA).

Research Disclaimer

This commissioned research report is provided solely for information. It does not constitute or form part of, and shall under no circumstances be considered as an offer to sell or a solicitation of an offer to purchase or sell any relevant financial instrument.

This commissioned research report has been requested and paid for by the issuer and should therefore be considered a marketing communication (i.e. not investment research). Payment for the report has been agreed in advance on a non-recourse basis. As commissioned research, this material can be considered an acceptable minor non-monetary benefit under MiFID II. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research. However, it is still subject to a prohibition on dealing ahead of the dissemination of the report.

Carnegie Investment Bank AB is responsible for the preparation of this commissioned research report in Sweden, Finland, Denmark, and the UK. Carnegie AS is responsible for the preparation of this commissioned research report in Norway. Carnegie Inc. is responsible for this research report in the US.

The information in this commissioned research report was obtained from various sources. While all reasonable care has been taken to ensure that the information is true and not misleading, Carnegie gives no representation or warranty, express or implied, about its accuracy or completeness. Carnegie, its subsidiaries and any of their officers or directors may have a position, or otherwise be interested in, transactions in securities that are directly or indirectly the subject of this commissioned research report. Any significant financial interests held by the analyst, Carnegie or a legal person in the same group in relation to the issuer will be referred to in the company-specific disclosures.

Company specific disclosures

The following disclosures relate to relationships between Carnegie Investment Bank AB (with its subsidiaries, "Carnegie") and the issuer or an affiliate.

Parts of this commissioned research report may have been submitted to the issuer prior to its publication.

Copyright © 2025 Carnegie



Commissioned Research sponsored by Stockwik

25 April 2025

Carnegie Investment Bank AB

Regeringsgatan 56
SE-103 38 Stockholm
Tel +46 8 5886 88 00 Fax +46 8 5886 88 95
www.carnegie.se
A member of the Stockholm Stock Exchange

Carnegie Investment Bank, Denmark Branch

Overgaden neden Vandet 9B PO Box 1935
DK-1414 Copenhagen K
Tel +45 32 88 02 00 Fax +45 32 96 10 22
www.carnegie.dk
A member of the Copenhagen Stock Exchange

Carnegie Investment Bank AB, Finland Branch

Eteläesplanadi 2 PO Box 36
FI-00131 Helsinki
Tel +358 9 618 71 230 Fax +358 9 618 71 720
www.carnegie.fi
A member of the Helsinki Stock Exchange

Carnegie AS

Fjordalleen 16, 5th Floor PO Box 684,
Sentrum NO-0106 Oslo
Tel +47 22 00 93 00 Fax +47 22 00 94 00
www.carnegie.no
A member of the Oslo Stock Exchange

Carnegie, Inc.

20 West 55th St. ,
New York N.Y. 10019
Tel +1 212 262 5800 Fax +1 212 265 3946
www.carnegiegroup.com
Member FINRA / SIPC

Carnegie Investment Bank AB, UK Branch

Finwell House, 26 Finsbury Square
London EC2A 1DS
Tel +44 20 7216 4000 Fax +44 20 7417 9426
www.carnegie.co.uk
Regulated by the FCA in the conduct of Designated
Investment Business in the UK